The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Barriers to clinical utilization of ADCs for lung cancer
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, comments on the challenges of implementing antibody-drug conjugates (ADCs) for lung cancer in the clinic. There is a need to address brain metastases in patients with actionable genomic alterations and to optimize the target of ADCs to improve delivery of the payload. It is also important of developing better methodologies to enhance sensitivity and specificity of biomarkers. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
